Interim analysis of the phase 3 LUNAR trial led to a recommendation to reduce the number of lung cancer patients required.
This recommendation is based on the strongly positive data gathered so far from the current patient population treated with tumor-treating fields.
About Tumor Treating Fields
When cancer develops, rapid and uncontrolled division of unhealthy cells occurs. Electrically charged proteins within the cell are critical for cell division, making the rapidly dividing cancer cells vulnerable to electrical interference.
As healthy cells differ from cancer cells in their division rate, geometry and electric properties, the frequency of TTFields can be tuned to specifically affect the cancer cells while leaving healthy cells mostly unaffected.
About the Study in Lung Cancer
The interim analysis included data taken from 210 patients with a data monitoring committee recommendation to reduce the sample size from 534 patients to approximately 276 patients.
It is possibly unethical given the available data.
Treatment in the TTFields arm of the current trial requires that patients wear 4 electrically insulated electrode arrays on the chest and that they maintain regular daily routine with the therapy.
There was no evidence of increased systemic toxicity when patients were treated with TTFields.
Contact us to find out what is the best treatment for YOU
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039